Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of small molecule therapies targeting age-related degenerative diseases and disorders of the central nervous system and retina. The company is headquartered in Purchase, New York.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-36.55M |
| Operating Margin | 0.00% |
| Return on Equity | -83.80% |
| Return on Assets | -78.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.35 |
| Price-to-Book | 2.01 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.44 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $95.09M |
| Float | $87.51M |
| % Insiders | 1.29% |
| % Institutions | 23.82% |
Volatility is currently expanding
Cognition Therapeutics NASDAQ: CGTX is preparing a Phase III trial of its experimental drug zervimesine in dementia with Lewy bodies after reaching alignment with the U.S. Food and Drug Administration on a planned registrational study, executives said on the company's third-quarter 2026 earnings call.
PURCHASE, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
-- Conference Call and Webcast 8:30 a.m. ET November 5 -- PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced that the Company will host a conference call and webcast on November 5, 2026, at 8:30 a.m. Eastern Time to report its financial results for the third quarter ended September 30, 2026, and provide a business update.
PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, has aligned with the U.S. Food and Drug Administration (FDA) on key elements of a Phase 3 study in dementia with Lewy bodies (DLB) including patient selection, dose, duration, and endpoints.
- An additional five years of patent protection may be possible through a standard extension - - An additional five years of patent protection may be possible through a standard extension -
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3 October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3
PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. Eastern Time. During her presentation, Ms. Ricciardi will discuss progress on the Company's development of zervimesine for Alzheimer's disease and dementia with Lewy bodies (DLB).
PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi, has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company's ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis.
Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CGTX and any ticker you trade — then tracks every position and per-strategy win rate.
